Jan 12 2010
DSG, a leader in electronic 
      data capture (EDC) has teamed up with a leading-edge pharmaceutical 
      technology company to speed the early detection of Alzheimer’s, 
      Parkinson’s, and Diabetes.
    
“We are delighted to provide this Pharma leader with the latest critical 
      technology solutions, helping to reach an incredibly important goal – 
      the early detection of debilitating diseases”
    
      The focus is on developing molecular imaging products that are leading 
      the way to the early detection of human diseases. DSG’s eCaseLink™ EDC 
      (Electronic Data Capture) supports three current clinical trials for Alzheimer’s 
      disease, Parkinson’s 
      disease and Diabetes. 
      eCaseLink™ supplies real-time capability to review case documents and 
      metrics across all study sites, significantly increasing clinical trial 
      management speed, while reducing study management costs by as much as 30 
      percent.
    
    
      DSG’s eCaseLink™ allows the pharmaceutical diagnostic and therapeutic 
      company not only to collect and manage their data in real time, but it 
      also gives them the option to add needed functionality as studies 
      progress. They have found that the innovation of the eCaseLink™ product 
      suite, combined with the experience and dedication of the DSG team, is 
      paying immediate and continued dividends for their clinical trial 
      management process.
    
    
      “We are delighted to provide this Pharma leader with the latest critical 
      technology solutions, helping to reach an incredibly important goal – 
      the early detection of debilitating diseases,” said Tony Varano, CEO, 
      DSG, Inc. “What is especially gratifying is that DSG provides select 
      solution modules specific to their needs, rather than the ‘cookie 
      cutter’ approach to most clinical trial data collection solutions.”
    
http://www.dsg-us.com/